Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma (NCT07300241)
An Open-Label, First-in-Human, Phase 1/2 Dose Escalation and Expansion Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.
Who can join: Review the eligibility criteria below.
Location: NEO-811 Los Angeles Site — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- NEO-811 Los Angeles Site — Duarte, California
- NEO-811 San Diego Site — San Diego, California
- NEO-811 Connecticut Site — New Haven, Connecticut
- NEO-811 Chicago Site — Zion, Illinois
- NEO-811 Grand Rapids Site — Grand Rapids, Michigan
- NEO-811 Omaha Site — Omaha, Nebraska
- NEO-811 Long Island Site — Lake Success, New York
- NEO-811 NYC Site — New York, New York
- NEO-811 South Carolina Site — Myrtle Beach, South Carolina
- NEO-811 Dallas Site — Dallas, Texas
- NEO-811 Houston Site — Houston, Texas
- NEO-811 Virginia Site — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (858) 428-9800
Email: clinicaltrials@neomorph.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Clear Cell Renal Cell Carcinoma
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery — Fairbanks, Alaska
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer — Los Angeles, California
- Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors — Duarte, California
- A Phase 1/2 Trial of ADI-270 in ccRCC — Redwood City, California
- Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab — Iowa City, Iowa
- Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer — Westwood, Kansas
Explore by condition: All Clear Cell Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.